copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
A Cutting-Edge Cancer Therapy Offers Hope for Patients With Lupus A Cutting-Edge Cancer Therapy Offers Hope for Patients With Lupus Lupus can be debilitating and sometimes deadly for the 3 million people who have it A treatment called CAR T appears to stop it in its tracks By Nina Agrawal, The New York Times, June 18, 2025 … CAR T-cell therapy, a kind of “living drug” that modifies patients’ immune cells to help them attack misbehaving ones, has
New Prospects for Difficult-to-Treat Lupus - medcentral. com A new CAR T-cell therapy for individuals with refractory systemic lupus erythematosus (SLE) proved to be nearly 100% effective in early phase research The US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to two investigative products – Fate Therapeutics’ FT819 and AbelZeta’s C-CAR168
Cancer Therapy Offers Hope for Lupus Treatment This Phase 1 international trial, named CARLYSE, is the UK’s first to evaluate CAR-T (Chimeric Antigen Receptor T-cell) therapy for a condition beyond cancer Involving 12 patients with lupus, also known as systemic lupus erythematosus (SLE), from various countries, the trial focuses on this chronic autoimmune disorder, where the immune
Upcoming studies give hope to people with lupus and MS Researchers are cautiously optimistic that the new use for a therapy with benefit in blood cancers could lead to life-changing results in lupus and MS The lupus trial is currently open for enrollment with the MS trial expected to begin enrolling patients early next year
Cancer therapy with potential to transform lupus treatment . . . Researchers hope that the one-off CAR-T therapy will reduce, or even remove, the need for life-long medication for patients with severe lupus The trial is led by UCL and University College London Hospitals NHS Foundation Trust (UCLH) and is sponsored by Autolus